Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237532 | 0.85 | POLB (0.36) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL4202389 | 0.85 | TSHR (0.44) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL29577269 | 0.85 | TSHR (0.44) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL2005854 | 0.83 | ALDH1A1 (0.52) | POLBALDH1A1MAPTKDM4ELMNA | |
| SCHEMBL236262 | 0.82 | THRB (0.37) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL238286 | 0.81 | TSHR (0.39) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL1372181 | 0.80 | THRB (0.42) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL31707533 | 0.80 | ALDH1A1 (0.52) | POLBAPEX1HTTTDP1TSHR | |
| SCHEMBL1716991 | 0.79 | THRB (0.44) | TSHRALDH1A1THRBLMNAPPARG | |
| SCHEMBL1781181 | 0.79 | POLB (0.36) | POLBAPEX1HTTTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110235262-B | Composition for organic electronic device sealant and sealant formed using the same | 莫门蒂夫性能材料韩国株式会社 | 2023-07-18 | — | — | CN | claimed |
| CN-112979863-A | Modified polyacrylate emulsion and application thereof in preparation of oil-proof and water-proof paper | 宁波市嘉化新材料科技有限公司 | 2021-06-18 | — | — | CN | claimed |
| US-10553824-B2 | Encapsulation composition for organic electronic device, and encapsulation formed using same | MOMENTIVE PERFORMANCE MATERIALS KOREA CO., LTD. (KR) | 2020-02-04 | — | — | US | claimed |
| US-20190341579-A1 | ENCAPSULATION COMPOSITION FOR ORGANIC ELECTRONIC DEVICE, AND ENCAPSULATION FORMED USING SAME | MOMENTIVE PERFORMANCE MATERIALS INC. | 2019-11-07 | — | — | US | claimed |
| EP-3565014-A1 | ENCAPSULATION COMPOSITION FOR ORGANIC ELECTRONIC DEVICE, AND ENCAPSULATION FORMED USING SAME | Momentive Performance Materials Korea Co., Ltd. (KR) | 2019-11-06 | — | — | EP | claimed |
| EP-1898264-B1 | Toner compositions | XEROX CORP (US) | 2016-04-06 | — | — | EP | claimed |
| US-8969429-B2 | Low-tack, hydrophobic ophthalmic device materials | NOVARTIS AG (CH) | 2015-03-03 | — | — | US | claimed |
| EP-2673666-B1 | LOW-TACK, HYDROPHOBIC OPHTHALMIC DEVICE MATERIALS | NOVARTIS AG (CH) | 2014-12-31 | — | — | EP | claimed |
| EP-2673666-A1 | LOW-TACK, HYDROPHOBIC OPHTHALMIC DEVICE MATERIALS | Novartis AG (CH) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109228-A1 | LOW-TACK, HYDROPHOBIC OPHTHALMIC DEVICE MATERIALS | NOVARTIS AG (CH) | 2012-08-16 | — | — | WO | claimed |
| US-20120202916-A1 | Low-Tack, Hydrophobic Ophthalmic Device Materials | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-8142970-B2 | Toner compositions | XEROX CORPORATION (US) | 2012-03-27 | — | — | US | claimed |
| WO-2004076566-A1 | ORGANIC-INORGANIC HYBRID COMPOSITE, PREPARATION THEREOF AND ANTI-FOGGING COATING COMPOSITION COMPRISING SAME | LUVANTIX CO., LTD. (KR) | 2004-09-10 | — | — | WO | claimed |
| EP-4749682-A1 | CURABLE COMPOSITION, FILM FORMING METHOD, AND METHOD FOR PRODUCING ARTICLE | Canon Kabushiki Kaisha (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20260140445-A1 | CURABLE COMPOSITION AND METHODS FOR FORMING FILM AND MANUFACTURING ARTICLE | CANON KK (JP) | 2026-05-21 | — | — | US | disclosed |
| US-20260126725-A1 | CURABLE COMPOSITION AND METHODS FOR FORMING FILM AND MANUFACTURING ARTICLE | CANON KK (JP) | 2026-05-07 | — | — | US | disclosed |
| WO-2004076465-A2 | SILYL ACRYLATE AND POSS COMPOSITIONS USED IN MICROLITHOGRAPHIC PROCESSES | BREWER SCIENCE INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-6506537-B2 | Photopolymerization | JSR CORPORATION (JP) | 2003-01-14 | — | — | US | disclosed |
| US-20020012872-A1 | Radiation-sensitive resin composition | JSR CORPORATION (JP) | 2002-01-31 | — | — | US | disclosed |
| EP-1164433-A1 | Radiation-sensitive resin composition | JSR Corporation (JP) | 2001-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260126725-A1 | CURABLE COMPOSITION AND METHODS FOR FORMING FILM AND MANUFACTURING ARTICLE | ATM, ATR, PIEZO1 | POLB 187/4885APEX1 598/4885HTT 1787/4885 |
| US-20260140445-A1 | CURABLE COMPOSITION AND METHODS FOR FORMING FILM AND MANUFACTURING ARTICLE | CFL1, ATM, PSPC1 | POLB 1593/4885APEX1 488/4885HTT 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.